Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the talking.
So the question, as narrowly as I can put it: what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work.
If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
jason_paloalto said:Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…
jason_paloalto said:...compounded vs brand cost and coverage...
This debate comes up weekly and I think both sides have valid points:
Pro-brand: FDA-approved, manufacturing standards guaranteed, clinical trial data directly applicable
Pro-compounded: 10x cost savings, same active molecule, independent testing available, accessibility
My position: if you can afford brand or have insurance coverage, that's the gold standard. If not, properly tested compounded from a 503B pharmacy is a reasonable alternative. Neither side should shame the other.
Dr.ObesityMed said:jason_paloalto said: ...compounded vs brand cost and coverage...
Dr.ObesityMed said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL Biochemjason_paloalto said:Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…
Can confirm. Same sequence, different timescale.
Clinical perspective, offered as context rather than as advice.
jason_paloalto said:...my insurance denied cost and coverage coverage because...
Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:
- Document medical necessity (BMI, comorbidities, failed alternatives)
- Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
- Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
- Request peer-to-peer review between your doctor and the plan's medical director
- File external appeal with your state insurance department if internal appeal fails
Don't accept the first denial. The appeal process exists for a reason.